NCT04386057View on ClinicalTrials.gov

LY3214996 +/- HCQ in Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

August 9, 2023

Study Completion Date

February 5, 2024

Conditions
Pancreatic CancerAdvanced Cancer
Interventions
DRUG

Hydroxychloroquine Sulfate

HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle

DRUG

LY3214996

LY3214996-daily oral dosage per protocol per 28 day cycle

Trial Locations (4)

27514

The University of North Carolina at Chapel Hill, Chapel Hill

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Kimberly Perez, MD

OTHER

NCT04386057 - LY3214996 +/- HCQ in Pancreatic Cancer | Biotech Hunter | Biotech Hunter